Dennis E. Marshall, a director at BioLargo, Inc., has exercised options to purchase a total of 515,623 shares of common stock. This significant transaction took place on September 30, 2026, and was reported in a recent SEC filing.
This development is noteworthy as it demonstrates Marshall's ongoing commitment to BioLargo and may influence investor confidence in the company's strategic direction. The exercise of stock options by directors often serves as a barometer of their belief in the company's future performance.
Background
BioLargo, Inc. is a company incorporated in Delaware, primarily engaged in the chemicals and allied products sector. The firm operates under the Central Index Key (CIK) 0000880242 and is known for its innovative technologies and solutions in industrial applications. The company has been actively filing with the SEC, with its most recent filings including Form 4 on October 2, 2026, and several others throughout 2026.
What the Filing Says
The SEC filing details that Marshall exercised options to purchase 281,248 shares at an exercise price of $0.08, and another set of 234,375 shares, also at the same price. Following these transactions, Marshall will own a total of 6,290,692 shares of BioLargo's common stock.
This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.
Impact
This move may affect various stakeholders, including investors and other directors within the chemicals and allied products industry. Marshall's decision to exercise these options could signal to investors that he believes in the company's potential for growth and success. Additionally, it may encourage other directors to consider similar actions in their respective companies.
What's Next
The filing does not say what happens next.